Medical oncology and tumor pharmacotherapy最新文献_第8页

5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature. 5-氟尿嘧啶(5FU)加或不加亚叶酸(LV)治疗人结直肠癌?文献的多元荟萃分析。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02987197

D Brohée

{"title":"5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.","authors":"D Brohée","doi":"10.1007/BF02987197","DOIUrl":"https://doi.org/10.1007/BF02987197","url":null,"abstract":"This meta-analysis is based on 106 evaluations of response from 77 clinical studies about 5-fluorouracil (5FU) treatment with or without leucovorin (LV) in metastatic colorectal carcinoma. Overall, in naive patients, LV is associated with a median response rate of 31% as compared with a 12% figure with 5FU alone. Using a forward stepwise multilinear regression analysis, it is shown that as much as 44% of the variance in the reported response rates in naive patients can be accounted for by treatment-related variables (P less than 0.001). The significant parameters are LV adjunction (partial R = 0.636), cumulative total 5FU dose (R = 0.344), and 5FU weekly schedule (R = 0.246). In pretreated patients, the latter parameter is the only significant one (R = 0.443). Unexpectedly, LV administration behaves like an all-or-nothing governor, without any obvious dose-effect relationship. Protracted 5FU infusion over weeks allows a mean cumulative drug delivery, 3 times higher than bolus regimens (21.3 vs 7.02 g m-2, P less than 0.001) and may represent the best clinical approach to influence the 5FU-related variables. Accordingly, it is suggested that 5FU protracted infusion, titrated to the highest tolerable doses and potentiated with low doses of leucovorin, could represent the most efficacious way for using 5FU in colorectal disseminated cancer. This hypothesis and its eventual impact on survival should be tested in randomized trials.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 4","pages":"271-80"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13002957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Glutathione S-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias. 白血病细胞谷胱甘肽s -转移酶活性作为急性白血病化疗反应的预后因素。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02988569

J Koberda, A Hellmann

{"title":"Glutathione S-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias.","authors":"J Koberda, A Hellmann","doi":"10.1007/BF02988569","DOIUrl":"https://doi.org/10.1007/BF02988569","url":null,"abstract":"This paper presents an analysis of glutathione S-transferase (GST) activity of leukemic cells in 30 patients with acute leukemias and its predictive value for therapy. Blast cells were isolated from peripheral blood or bone marrow before induction therapy using Ficoll density gradient. GST activity was measured according to the spectrophotometric assay based on the use of 1-chloro-2,4-dinitrobenzene as a substrate. The results did not show any significant differences between activities of the enzyme within the different leukemia types according to the French-American-British (FAB) classification. The patients who achieved complete remission demonstrated the lowest value of enzyme activity. The highest enzyme activity was observed in those patients who achieved partial remission and the non-responsive patients presented a GST value within the median of these two groups. Two categories of patients were represented within the non-responsive treatment group. One was resistant to the conventional therapy and in the other death was caused by infectious or hemorrhagic complications. The mean GST activity in these two groups of patients differ greatly. These results suggest that low GST activity of leukemic cells could be a favourable prognostic factor whereas high GST values could help to find out the group of patients who should be further analysed prior to induction therapy.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 1","pages":"35-8"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02988569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13197710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Hemopoietic stem-cell differentiation in fetal liver, spleen and thymus of rhesus monkeys. 恒河猴胎肝、脾和胸腺造血干细胞分化的研究。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02988863

S Sharma, A Karak, D N Sharma, S Aggarwal

引用次数: 4

Interaction between cytostatics and nutrients. 细胞抑制剂和营养物质之间的相互作用。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02988858

R Henriksson, K O Rogo, K Grankvist

引用次数: 5

Mammography. 乳房x光检查。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02987180

J Pontén

引用次数: 0

Chemotherapy and immunotherapy of colorectal cancer. 结直肠癌的化疗和免疫治疗。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02987181

G Masucci, P Ragnhammar, J E Frödin, A L Hjelm, P Wersäll, J Fagerberg, A Osterborg, H Mellstedt

{"title":"Chemotherapy and immunotherapy of colorectal cancer.","authors":"G Masucci, P Ragnhammar, J E Frödin, A L Hjelm, P Wersäll, J Fagerberg, A Osterborg, H Mellstedt","doi":"10.1007/BF02987181","DOIUrl":"https://doi.org/10.1007/BF02987181","url":null,"abstract":"More than 50% of the patients with large bowel cancer develop disseminated disease and invariably succumb. Adjuvant chemotherapy with 5-FU and levamisole have been shown to be more efficient than 5-FU alone or in combination with cytostatics. The combination of 5-FU, leukovorin and methotrexate induces prolonged survival with a good quality of life in metastatic colorectal cancer (CRC). During the last decade tumor immunotherapy has been an alternative facilitated by isolation and large scale production of cytokines and monoclonal antibodies. The mouse monoclonal antibody (MAb) 17-1A recognizes a tumor-associated antigen (TAA), present in high concentrations on the surface of gastrointestinal tumor cells. Injections of MAb 17-1A in patients with metastatic CRC induced generation of anti-idiotypic (ab2) in 90% and anti-anti-idiotypic (ab3) antibodies in 47% of the treated patients. The development of ab3 correlated significantly with survival (mean 80 weeks) while ab3- patients survive only 38 weeks. One of 52 patients treated with MAb 17-1A is a complete remission after 66 months, 3 had minor regression and 6 had a stable disease (19% RR). Based on in vitro findings showing increased antibody-dependent cellular cytotoxicity (ADCC) by the combination of granulocyte-macrophage colony stimulating factor (GM-CSF) and MAb 17-1A, 16 CRC patients have been treated with subcutaneously injections of GM-CSF for 10 days and intravenous infusions of MAb 17-1A at day 3. Two of 16 are in CR, 1 in MR and 3 in SD (37.5% RR). Minor side-effects were registered. A further development of immunotherapy of CRC might imply vaccination by injection of specific human anti-idiotypic antibodies (ab2) which mimics the nominal antigen, in order to induce a specific immunity.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 3","pages":"207-20"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12964872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Monoclonal antibodies in the management of carcinoma patients. 单克隆抗体在肿瘤患者治疗中的应用。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02987190

M Roselli, C U Casciani, F Guadagni, O Buonomo, B Iorio, A Diodati, V Vittorini, J W Greiner, D Colcher, J Schlom

引用次数: 2

Total body hyperthermia in the treatment of Kaposi's sarcoma in an HIV positive patient. 全身热疗治疗HIV阳性患者卡波西肉瘤。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02988571

W D Logan, K Alonso

引用次数: 7

Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. 混合细菌疫苗辅助治疗肝癌的初步结果。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02988567

Z Y Tang, H Y Zhou, G Zhao, L M Chai, M Zhou, J Z Lu, K D Liu, H F Havas, H C Nauts

{"title":"Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma.","authors":"Z Y Tang, H Y Zhou, G Zhao, L M Chai, M Zhou, J Z Lu, K D Liu, H F Havas, H C Nauts","doi":"10.1007/BF02988567","DOIUrl":"https://doi.org/10.1007/BF02988567","url":null,"abstract":"Mixed bacterial vaccine (MBV) was employed in the multi-modality treatment of hepatocellular carcinoma (HCC) during 1985-1988. Thirty eight patients undergoing palliative resection and cisplatin therapy (Series 1) and 48 patients with unresectable HCC who received hepatic artery ligation + intraarterial cisplatin infusion + radiotherapy (Series 2) were randomized to receive MBV or not. In series 1, the 1- and 2-year survival rates of MBV group and control were 75% vs 58% (P = 0.19) and 45% vs 39% (P = 0.23). In series 2, the 1-, 2- and 3-year survival rates were 59%, 41% and 41% for MBV group and 39%, 25% and 20% for the control, respectively (P1 = 0.07, P2 = 0.09, P3 = 0.07). In addition, MBV improved the \"second look\" resection rate to 40% as compared to 17% in the control (P greater than 0.05). MBV could also prevent such immunosuppression as decrease of macrophage activity caused by radiotherapy. We consider MBV a potential nonspecific immunostimulant in the multimodality treatment of HCC.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 1","pages":"23-8"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02988567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12811827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Monoclonal 3C6F9 distribution in human breast carcinomas: image cytometry of immunocytochemical assays. 单克隆3C6F9在人乳腺癌中的分布:免疫细胞化学检测的图像细胞术。

Medical oncology and tumor pharmacotherapy Pub Date : 1991-01-01 DOI: 10.1007/BF02987193

C Charpin, M J Dicaire, B Barbeau, M N Lavaut, C Andonian, B Devictor, C Allasia, P Bonnier, R Mandeville

{"title":"Monoclonal 3C6F9 distribution in human breast carcinomas: image cytometry of immunocytochemical assays.","authors":"C Charpin, M J Dicaire, B Barbeau, M N Lavaut, C Andonian, B Devictor, C Allasia, P Bonnier, R Mandeville","doi":"10.1007/BF02987193","DOIUrl":"https://doi.org/10.1007/BF02987193","url":null,"abstract":"MoAbF9 immunoreactivity was investigated in frozen sections of 123 breast carcinomas using an avidin or streptavidin biotin peroxidase kit. A standardized computer image analysis system was used to evaluate immunostaining. The percent of cell surface staining and mean optical densities were correlated with morphological criteria of prognosis such as tumor size histological grade, blood and lymph invasion and axillary lymph node involvement, with immunoreactivity to other MoAb, i.e. Ki67, anti-RE and anti-RP, anti-p.HER-2/neu and with tumor aneuploidy and AgNORs content in tumor cell nuclei. Despite some heterogeneity, MoAbF9 was reactive with all breast carcinomas tested. The percent of F9 immunostained cell surface and mean optical density increased with Ki67 immunoreactivity, tumor aneuploidy and AgNORs nucleus surface but were independent of p.HER-2/neu oncoprotein distribution and tumor receptor content. These findings suggest that F9 could not only allow detection axillary lymph node micrometastases but also be used as plasmatic marker for tumor recurrence and metastases.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 4","pages":"243-51"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987193","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12982263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2